U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940765) titled 'Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19' on Aug. 19, 2021.
Brief Summary: This study is an early feasibility study to evaluate the safety of a single intravenous injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of continuing respiratory distress after recovery from COVID-19.
Study Start Date: Sept., 2021
Study Type: INTERVENTIONAL
Condition:
Covid19
Intervention:
DEVICE: GID SVF-2 Device System
The GID SVF-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction ce...